About Sangamo Therapeutics, Inc. - Common Stock (SGMO)
Sangamo Therapeutics is a biotechnology company focused on developing groundbreaking gene-editing therapies and genomic medicine to address a range of genetic diseases and disorders. By leveraging its expertise in gene modulation and genome editing technologies, including zinc finger proteins, the company aims to create innovative treatments that can permanently alter or correct genetic mutations at the DNA level. Sangamo is committed to advancing its pipeline of therapeutic candidates through rigorous research and clinical trials, collaborating with a variety of partners to expedite the development of transformative therapies for patients in need. Read More
The stock market experienced a significant downturn today, with the S&P 500 dropping nearly 5% to 5,396.52, marking its worst session since September 2022.
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Sangamo Therapeutics shares are surging in Thursday's after-hours session after the company announced a new agreement with pharmaceutical giant Eli Lilly And Co.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has entered into a license agreement with Eli Lilly and Company (“Lilly”), allowing Lilly to leverage Sangamo’s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, which has demonstrated potent blood-brain barrier penetration and neuronal transduction in nonhuman primates. The agreement grants Lilly a worldwide exclusive license to utilize the STAC-BBB capsid for one initial target, with the right to add up to four additional targets after paying additional licensed target fees, to deliver their intravenously administered genomic medicines to treat certain diseases of the central nervous system.
Several optimistic users expressed confidence in the company securing a third potential agreement with a major pharma for its adeno-associated virus (AAV) capsid, STAC-BBB.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and fourth quarter and full year 2024 financial results.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2024 financial results after the markets close on Monday, March 17, 2025. The company also plans to participate in an upcoming investor conference.
Pfizer has discontinued Beqvez for hemophilia B due to low patient demand and will focus on alternative treatments, including its approved therapy, Hympavzi.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. Updated data continue to support the potential of isaralgagene civaparvovec as a one-time, durable treatment option for Fabry disease that can improve patient outcomes.
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of Sangamo Therapeutics, Inc. (“Sangamo” or the “Company”) (NASDAQ: SGMO) on behalf of investors concerning the Company’s possible violations of federal securities laws.
